Meeting
2014 Gastrointestinal Cancers Symposium
Second-line gemcitabine plus nab-paclitaxel (G+A) for advanced pancreatic cancer (APC) after first-line FOLFIRINOX: Single institution retrospective review of efficacy and toxicity.
Authors
Yue Zhang
Yale University School of Medicine, New Haven, CT
Yue Zhang , Howard S. Hochster , Stacey Stein , Jill Lacy
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 32, 2014 (suppl 3; abstr 344)
DOI
10.1200/jco.2014.32.3_suppl.344
Abstract #
344
Poster Bd #
D3
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
First-line chemotherapy regimens associated with survival in advanced pancreatic cancer: A Mexican single-center, real-world study.
First Author: Marytere Herrera
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Efficacy of the third-line chemotherapy in patients with advanced pancreatic cancer.
First Author: Bomi Kim
Poster
2021 Gastrointestinal Cancers Symposium
AGIG chemo-immunotherapy in patients with advanced pancreatic cancer: A single-arm, single-center, phase II study.
First Author: Wangshu Dai
Poster
2019 Gastrointestinal Cancers Symposium
Real world usage of gemcitabine and nabpaclitaxel in older adults with metastatic pancreatic cancer: A single institution experience.
First Author: Arthur Winer